Revolution Medicines, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Revolution Medicines, Inc. (RVMD) reported Net Income (Loss) Available to Common Stockholders, Basic of -$644.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-05
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$644.37M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$453.82M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$364.89M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$305.21M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$1.13B.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$600.09M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$436.37M.
- Revolution Medicines, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$248.71M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$644.37M 10-Q · filed 2026-08-05 | -$1.10B 10-Q · filed 2026-08-05 | -$1.46B derived: sum of 3 quarters · filed 2026-08-05 | -$1.77B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$453.82M 10-Q · filed 2026-05-06 | -$818.71M derived: sum of 2 quarters · filed 2026-05-06 | -$1.12B derived: sum of 3 quarters · filed 2026-05-06 | -$1.37B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$364.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$670.10M derived: sum of 2 quarters · filed 2026-02-25 | -$917.88M derived: sum of 3 quarters · filed 2026-08-05 | -$1.13B 10-K · filed 2026-02-25 |
| 2025-09-30 | -$305.21M 10-Q · filed 2025-11-05 | -$552.99M derived: sum of 2 quarters · filed 2026-08-05 | -$766.41M 10-Q · filed 2025-11-05 | -$960.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$247.79M 10-Q · filed 2026-08-05 | -$461.20M 10-Q · filed 2026-08-05 | -$655.77M derived: sum of 3 quarters · filed 2026-08-05 | -$812.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$213.42M 10-Q · filed 2026-05-06 | -$407.99M derived: sum of 2 quarters · filed 2026-05-06 | -$564.27M derived: sum of 3 quarters · filed 2026-05-06 | -$697.51M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$194.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$350.86M derived: sum of 2 quarters · filed 2026-02-25 | -$484.09M derived: sum of 3 quarters · filed 2026-02-25 | -$600.09M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$156.29M 10-Q · filed 2025-11-05 | -$289.52M derived: sum of 2 quarters · filed 2025-11-05 | -$405.52M 10-Q · filed 2025-11-05 | -$567.06M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$133.23M 10-Q · filed 2025-08-06 | -$249.24M 10-Q · filed 2025-08-06 | -$410.77M derived: sum of 3 quarters · filed 2026-02-25 | -$519.21M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$116.00M 10-Q · filed 2025-05-07 | -$277.54M derived: sum of 2 quarters · filed 2026-02-25 | -$385.97M derived: sum of 3 quarters · filed 2026-02-25 | -$484.27M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$161.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$269.97M derived: sum of 2 quarters · filed 2026-02-25 | -$368.27M derived: sum of 3 quarters · filed 2026-02-25 | -$436.37M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$108.43M 10-Q · filed 2024-11-06 | -$206.73M derived: sum of 2 quarters · filed 2024-11-06 | -$274.83M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$98.30M 10-Q · filed 2024-08-07 | -$166.40M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$68.10M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$248.71M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$52.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$105.62M derived: sum of 2 quarters · filed 2024-02-26 | -$149.91M derived: sum of 3 quarters · filed 2024-02-26 | -$187.09M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$52.94M 10-Q · filed 2021-11-10 | -$97.24M derived: sum of 2 quarters · filed 2021-11-10 | -$134.41M 10-Q · filed 2021-11-10 | -$168.62M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$44.30M 10-Q · filed 2021-08-11 | -$81.47M 10-Q · filed 2021-08-11 | -$115.68M derived: sum of 3 quarters · filed 2023-02-27 | -$142.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$37.18M 10-Q · filed 2021-05-10 | -$71.38M derived: sum of 2 quarters · filed 2023-02-27 | -$98.60M derived: sum of 3 quarters · filed 2023-02-27 | -$125.82M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$34.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$61.42M derived: sum of 2 quarters · filed 2023-02-27 | -$88.64M derived: sum of 3 quarters · filed 2023-02-27 | -$110.38M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$27.22M 10-Q · filed 2021-11-10 | -$54.44M derived: sum of 2 quarters · filed 2021-11-10 | -$76.17M 10-Q · filed 2021-11-10 | -$95.02M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$27.21M 10-Q · filed 2021-08-11 | -$48.95M 10-Q · filed 2021-08-11 | -$67.80M derived: sum of 3 quarters · filed 2022-02-28 | -$84.86M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$21.74M 10-Q · filed 2021-05-10 | -$40.59M derived: sum of 2 quarters · filed 2022-02-28 | -$57.65M derived: sum of 3 quarters · filed 2022-02-28 | -$70.83M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$18.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$35.91M derived: sum of 2 quarters · filed 2022-02-28 | -$49.09M derived: sum of 3 quarters · filed 2022-02-28 | -$61.90M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$17.07M 10-Q · filed 2020-11-12 | -$30.25M derived: sum of 2 quarters · filed 2020-11-12 | -$43.05M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$13.18M 10-Q · filed 2020-08-10 | -$25.99M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$12.81M 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | -$48.82M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |